logo
BLS firing 'erodes institutional integrity': Mohamed El-Erian

BLS firing 'erodes institutional integrity': Mohamed El-Erian

Yahoo4 days ago
Queens College Cambridge president Mohamed El-Erian joins Morning Brief with Julie Hyman to discuss President Trump's firing of the Bureau of Labor Statistics (BLS) chief.
To watch more expert insights and analysis on the latest market action, check out more Morning Brief.
President Trump reiterated his criticism of the Bureau of Labor Statistics, said he was close to picking a new Fed chair and teased new tariffs on semiconductors. Joining me now, Mohamed El-Erian, President of Queen's College, Cambridge to talk about that and many other things. Mohamed, good to see you.
Good morning, Julie.
I would like to start with this whole situation over the Bureau of Labor Statistics, the BLS. Um with President Trump's removal of the person who heads up that agency, what does that do to confidence in future statistics? We've got, for example, CPI coming next week from that agency.
So, I think the three takeaways, Julie. The first one is that the way the head was fired, and she was fired just following data releases that the president like, that erodes institutional integrity. And institutional integrity is very important um in the US economy. The second focus is on the problems we having collecting and estimating data. These have been long-standing problems that have been getting worse. Um as you know, the reporting level has come down. As you know, the methodology used for estimating when you don't have the data um is breaking down. So, there are fundamental issues that have to be addressed and that includes not incorporating enough new data new data sources because we saw during the pandemic that there are all sorts of non-conventional data sources that shed a lot of light. But the third issue, the one that's not talked enough about, is when you tend to have such large revisions, they tend to be at point of economic inflection. They tend to be when things are changing in the underlying economy and the data simply cannot keep up with what's changing. And I think that third element is going to be important as we go forward.
Okay. So, let's dig into that third element because that revision those revisions were alarming, right? And on Friday it seemed to sort of fundamentally shake the assumptions that a lot of market participants had had about the labor market, that it was holding up okay. So, A, do we believe those revisions? Do they reflect what's going on? And how concerned are you then about the labor market?
So I think the revisions are consistent with a lot of anecdotal data that comes from talking to households, that comes from looking at companies' earnings. And what you basically get is the following, pricing power for those who sell to low household incomes is very low because low household income income, low income households are suffering. We also have seen other signs of weakness. So I think what the labor revisions have picked up is a weakening economy, not an economy going into recession, but a weakening economy. And ironically, two days later in terms of trading sessions, the bond market has priced in a weaker economy. The pricing of Fed cuts, that probability, as we heard, is up to 90%. So the fixed income side of the markets has understood what the data is telling us. The equity side is being supported in a fundamental way by two things. One is the notion of FOMO. Every time you bought a dip recently in in the recent few years, it has been profitable. So people have been conditioned to buy a dip. And second, this distinction between tech and AI and the rest. And tech and AI is enough of a locomotive to drive the whole market up.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Cardinal Health expands urology focus with $1.9bn Solaris Health deal
Cardinal Health expands urology focus with $1.9bn Solaris Health deal

Yahoo

time19 minutes ago

  • Yahoo

Cardinal Health expands urology focus with $1.9bn Solaris Health deal

US drug distributor Cardinal Health has signed a $1.9bn agreement to acquire a majority stake in Solaris Health from Lee Equity Partners. The deal aims to expand the Specialty Alliance, the distributor's multi-speciality management services organisation (MSO) platform, in which Cardinal will gain a stake of around 75%. The acquisition will also create the Urology Alliance, comprising a collaborative network of urology providers within Cardinal's Specialty Alliance MSO, as well as resonate with plans to expand the delivery of urological patient care. Cardinal's Solaris buyout complements its recent acquisitions of Urology America, Potomac Urology, and Academic Urology & Urogynaecology, signalling its urologic strategy. The transaction is expected to be completed by the end of this year, pending customary closing conditions. Cardinal Health CEO Jason Hollar stated that growing the Speciality Alliance is a 'top priority' for the company, with the latest urology purchase leaving it 'well-positioned to meet the comprehensive needs of community urologists through the robust combined capabilities of the Specialty Alliance, Specialty Networks and Cardinal Health'. Research indicates there is a shortage of urologists in the US, with 62% of US counties lacking a practising urologist and just one new urologist entering the field for every ten retiring. The figures lead to challenges in the broader field, including delayed diagnoses, increased rates of advanced-stage conditions, and significant health disparities, with these particularly pronounced in rural communities. GlobalData's senior medical analyst Selena Yu foresees Cardinal's acquisition as reflecting a shift from drug distribution with a 'lower profit margin, towards higher margin speciality care in urology'. Yu said: 'MSOs help streamline backend work like billing and staffing to allow for physicians to focus on care. 'Additionally, with a large network of specialists, patients can receive care in the same region by different care specialists, which will reduce wait times and improve care continuity. Additionally, the Cardinal Health Alliance has other specialities like oncology specialists, which makes referrals more streamlined.' Cardinal's acquisition coincided with the release of its Q4 2025 financials. The company's profits per share came in at $2.08, beating the forecasted $2.03, yet profits for the quarter came in at $60.2bn, below the $60.92bn forecast, prompting a pre-market stock drop of more than 11% on 12 August. Cardinal's share price has since recovered to a drop of around 6% to $147.05 per share, down from $157.66 per share at market close on 11 August. "Cardinal Health expands urology focus with $1.9bn Solaris Health deal" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Effettua l'accesso per consultare il tuo portafoglio

Texas sues Eli Lilly for allegedly bribing providers to prescribe its medications
Texas sues Eli Lilly for allegedly bribing providers to prescribe its medications

Yahoo

time19 minutes ago

  • Yahoo

Texas sues Eli Lilly for allegedly bribing providers to prescribe its medications

WASHINGTON (Reuters) -Texas Attorney General Ken Paxton on Tuesday sued U.S. drugmaker Eli Lilly for allegedly "bribing" providers to prescribe its medications. The attorney general's office said in a statement that the company bribed and illegally induced medical providers to prescribe its most profitable drugs, including the GLP-1 medications Mounjaro and Zepbound, used for weight loss and diabetes treatment. "Big Pharma compromised medical decision-making by engaging in an illegal kickback scheme," Attorney General Paxton said. The lawsuit builds upon Attorney General's previous legal action to hold drug manufacturers accountable for fraud and abuse, the statement added. Last year, Paxton had sued insulin manufacturers, including Lilly and pharmacy benefit managers (PBMs), alleging that manufacturers artificially raised the prices of insulin and then paid a significant, undisclosed portion back to the PBMs for preferential treatment in return. Eli Lilly did not immediately respond to a Reuters request for comment. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store